The tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) were approved for use in treating non-small cell lung cancer (NSCLC). Here we presented a case of a male patient with stage IIIA NSCLC treated with osimertinib for 4.5 months in the neoadjuvant setting, and followed by tumor resection. The patient continued osimertinib treatment after surgery. No recurrence or metastasis was found in the postoperative reexamination. This case report suggested that osimertinib may be effective as neoadjuvant therapy for resectable stage III NSCLC.